Network pharmacology analysis of pharmacological mechanisms underlying the anti-type 2 diabetes mellitus effect of guava leaf

Abstract

The current study aimed to explore the anti-type 2 diabetes mellitus (T2DM) mechanism of guava leaf based on network pharmacology. The compounds contained in guava leaf was summarized from the literature, and a series of databases was used to identify the active components and corresponding potential targets. The intersection between diabetes-associated genes searched in the GeneCard database and the predicted targets of guava leaf active components was defined as target genes, which were then used to construct a “compound-active components-target genes” pharmacological network. The biological functions and pathway enrichment analyses of target genes were performed in KOBAS 3.0. The differential expression analysis of GSE76894 was performed to obtain the differential expressed genes (DEGs) in T2DM patients by comparing non-diabetic controls. Finally, the intersection between DEGs and target genes were named key genes, and the representative pathways in which these genes were involved were drawn through KEGG Mapper. We found that the active components of guava leaf may regulate the PI3K-AKT signaling pathway, T2DM regulation process, and insulin resistance pathway, which was evidenced by KEGG pathway analysis of key genes. These results implied that guava leaf has a potential anti-T2DM property and its mode of action may be exerted via regulating insulin secretion and reducing blood sugar level.

Keywords

• Guava leaf
• Network pharmacology
• Type 2 diabetes mellitus
• Flavonoid
• Triterpenoid
• Meroterpenoid